Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on October 5, 2026
Bayer commits $2.2 billion to an Ohio drugmaking campus
Alvotech won FDA clearance to double Simlandi drug-substance capacity for US supply, while HORIBA opened a customer laboratory in New Jersey.
Today in brief
Bayer plans a $2.2 billion pharmaceutical manufacturing campus in New Albany, Ohio, with its first drug-substance module scheduled to open in 2031.12 A second Reykjavik suite is now cleared to make Simlandi drug substance for the US, doubling Alvotech’s capacity for that market.3
Bayer plans a phased Ohio manufacturing campus
Bayer plans to build a $2.2 billion pharmaceutical manufacturing campus at New Albany International Business Park in Ohio.12 The company said the modular site would use automated and digital systems to make drug substances, the active ingredients, and finished drug products.1
Bayer expects the facility to support medicines in cardiovascular, oncology, and renal care.12 The first drug-substance module is scheduled to open in 2031, followed by a drug-product unit in 2034.12 Construction is expected to generate about 1,500 jobs, and the operating site is projected to support roughly 600 permanent roles.12
Bayer said it plans to connect the site to a US network linking commercial manufacturing and academic research.1 The company said it has committed more than $7 billion to US pharmaceutical research, development, and manufacturing over five years.1
Alvotech gets a second Simlandi production suite cleared for US supply
The FDA approved Alvotech’s application to produce AVT02, sold in the US as Simlandi, in a second drug-substance suite at its Reykjavik facility.3 The authorization doubles capacity available for US supply and adds operational flexibility.3
The suite handles the full drug-substance process, from cell culture through purification, and already had commercial authorization for European markets.3 In April 2023, the FDA issued a complete response letter for AVT02, citing facility deficiencies that needed correction.3 The FDA’s July 2026 inspection of the Reykjavik site ended with a Voluntary Action Indicated classification. It requires a written response and is less severe than a warning letter.3
Teva is Alvotech’s exclusive US commercialization partner for Simlandi, while Alvotech handles development and manufacturing.3 Alvotech cautioned that each pending application tied to the site still requires its own FDA review and decision.3
Also worth knowing
-
HORIBA opened a 15,000-square-foot Analytical Solution Plaza in Piscataway, New Jersey, where customers can work with company scientists on applications and methods development, including in life sciences and biopharma.4
Also published
- Logipharma USA 2026: Building Resilient Supply Chains at Scale Pharmaceutical Commerce
- Membrane Chromatography: Helping Downstream Processing To Follow Upstream Innovation BioProcess International
- How Distribution Is Evolving for Today's Targeted Therapies Pharmaceutical Commerce
- How AI is transforming biopharma manufacturing facilities of the future BioPharma Dive
- BIO on the American Road visits pioneering NC biotech hub Bio.News
- Designing biologics for commercial success European Biotechnology
- Bayer pledges $2.2bn to US manufacturing facility pharmaphorum